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Abstract
Clinical pharmacology as a scientific discipline and medical specialty was unarguably born in the twentieth century. Whilst
pharmacology—the science behind the treatment of disease—had been in evolution since at least medieval times, the clinical
discipline of pharmacology has had a more recent genesis and rather insidious evolution. During the 1900s, there were some clear
father (parent) figures of clinical pharmacology in Europe that emerged and were responsible for the development of the specialty
in this continent. This was a time when there were parallel developments in geographically dispersed academic departments
(around the globe), during an age of excitement in drug discovery and clinical application of new therapeutic agents. It was the
meeting of minds of some of these progenitors of the specialty that led to the development of the European Association for
Clinical Pharmacology and Therapeutics (EACPT) 25 years ago arising from a working party supported by the World Health
Organization in Europe. The EACPT now includes all major national organizations for clinical pharmacology in Europe,
representing over 4000 individual professionals interested in clinical pharmacology and therapeutics. The EACPT has a major
interest in promoting the safe use of medicines across Europe and internationally and has supported these aims since 1995,
through biennial international scientific congresses and summer schools with delegates and presenters from around the world as
well as various working group activities. In this article, the current executive committee members of EACPT recall this history,
describe the evolution of the association over the last quarter of a century, and provide an update on the activities and ambitions of
the association today.
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Background
Clinical pharmacology as a scientific discipline and medical
specialty was unarguably born in the twentieth century [1].
Whilst pharmacology—the science behind the treatment of
disease—had been in evolution since at least medieval times
[2], the clinical discipline of pharmacology has had a more
recent genesis and rather insidious evolution. During the
1900s, there were some clear father (parent) figures of clinical
pharmacology in Europe that emerged and were responsible
for the development of the specialty in this continent. This was
a time when there were parallel developments in geographi-
cally dispersed academic departments (around the globe), dur-
ing an age of excitement in drug discovery and clinical appli-
cation of new therapeutic agents. It was the meeting of minds
of some of these progenitors of the specialty that led to the
development of the European Association for Clinical
Pharmacology and Therapeutics (EACPT) 25 years ago aris-
ing from a working party supported by the World Health
Organization in Europe. The EACPT now includes all major
national organizations for clinical pharmacology in Europe,
representing over 4000 individual professionals interested in
clinical pharmacology and therapeutics. The EACPT has a
major interest in promoting the safe use of medicines across
Europe and internationally and has supported these aims since
1995, through biennial international scientific congresses and
summer schools with delegates and presenters from around
the world as well as various working group activities. In this
article, the current executive committee members of EACPT
recall this history, describe the evolution of the association
over the last quarter of a century, and provide an update on
the activities and ambitions of the association today.
History of clinical pharmacology
as a discipline
There have been many articles that have eloquently described
the origin of the term clinical pharmacology, and these will not
be reproduced here in detail. Clinical pharmacology really
evolved in the mid Twentieth century during a time of phar-
macological revolution, a time when there was a realization
that neither the dose nor the mechanism of action ofmany new
small molecule drugs can always predict the clinical response.
(One size does not always fit all!) Thus, many clinical phar-
macology groups stemmed from analytical chemistry labora-
tories studying drug disposition of these new drugs. However,
the discipline was more than just pharmacokinetic studies as
clinical pharmacologists also became important figures in the
design and evaluation of experimental and clinical trials, drug
safety studies, and epidemiological research on drugs, as well
as a hands-on clinical discipline offering advice on drug-
related issues.
Clinical pharmacology as a bridging discipline between
basic and applied research was carving out its own niche in
science and practice throughout Europe. It was not surprising
that with generation of new evidence in this area that there
came the inception of specific journals dedicated to the
methods and concepts of clinical pharmacology. In 1968, the
new journal Pharmacologica Clinica was founded in a col-
laboration between the publisher Springer Verlag and
Professor Dr. Hans Dengler from the University of
Heidelberg, Germany [3]. Dengler (1925–1997) championed
the cause of clinical pharmacology throughout his life and was
instrumental in the discipline’s uptake in Germany. Two years
later the journal was renamed the European Journal of Clinical
Pharmacology and is the current EACPT supported journal in
2019. From the early 1970s onwards, the journal has been
championed by a number of figure-head colleagues within
the growing field of clinical pharmacology as managing edi-
tors and contributors; the majority of which have also been
active in EACPT activities.
The British Journal of Clinical Pharmacology (BJCP) was
first published in 1974, four years after the clinical section of
the longstanding British Pharmacological Society (established
in 1934) had first met. This further new journal on the topic
initially appeared bi-monthly containing articles relating to all
aspects of drug action in man [4]. The first editor in chief of
BJCP was Professor Graham Wilson from Glasgow, a man
whose influence did much to get clinical pharmacology ac-
cepted as a specialty in its own right in Britain.
The origins of clinical pharmacology in some European
countries may have pre-dated the formal birth of EACPT,
but many countries were kindled by EACPT into devel-
opment of the specialty on a national basis. (The EACPT
committee are working on describing this interesting par-
allel development of the specialty of clinical pharmacolo-
gy across Europe for a future publication). Nevertheless,
there was overall rapid growth across Europe in the twen-
tieth century (and in particular, in the 1960s and 1970s) of
clinical pharmacology. The seminal step in the develop-
ment of the discipline was the convening of a study group
on clinical pharmacology in the European Offices of the
World Health Organization in 1969. This group set out to
demarcate the scope of the new discipline of clinical phar-
macology, to promote the need for trained specialists in
the subject, and encourage the coordination and appropri-
ate scientific conduct of drug studies: the group reported
their findings in 1970 [5].
Gestation and birth of EACPT
It was in the early 1990s that a group of clinical pharma-
cologists met in Verona (Italy) to consider creating a
Europe-wide body to encourage clinical pharmacology
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and therapeutic interests throughout Europe. This follow-
ed conversations that had started in the World Health
Organization Working Group in the decade before. After
wider consultation, a committee was created in 1993 un-
der the chairmanship of Prof Folke Sjöqvist (Sweden)
with the remit to prepare the first congress of EACPT,
which was held in Paris in 1995. The interim committee
also consisted of Georges Cheymol (France, Vice-
Chairman), Norbert Rietbrock (Germany, Treasurer),
Michael Orme (UK, Secretary) and committee members
Pierre Bechtel (France), Jochen Kuhlmann (Germany),
Allan Struthers (UK), Per Knut Lunde (Norway), Joan-
Ramon Laporte (Spain), Leo Offerhaus (The Netherlands
and WHO Europe) and Giampaolo Velo (Italy) [6].
However, the association became a formally registered as-
sociation in August 1994 in German Law, which makes us
25 years’ old in this calendar year of 2019.
It was in the Paris congress in 1995 that a formal con-
stitution was agreed by the council formed by representa-
tive delegates of all at that time 26 countries involved.
The statutes, which had been drafted by the interim com-
mittee, were confirmed and set out how the association
should realize its aims to develop the specialty across
Europe. It is a testament to the foresight of our societal
forefathers that the original aims and objectives remain
extant, and most importantly still very relevant in today’s
activities of the association (Table 1).
EACPT activities over the last 25 years
From the beginning of EACPT in the early 1990s, EACPT
meetings were organized to improve the interaction between
clinical pharmacologists all over Europe, setting the stage for
a clinical pharmacology network in research, teaching, and
(public) health care. During the large meetings that were or-
ganized every other year, all fields of clinical pharmacology
were covered. More recently the association has initiated part-
nerships with other societies outside Europe (such as South
America and Korea) in order to enhance partnership, visibility,
and networking. Starting from 2015 onwards, the organization
of these biannual meetings has been harmonized by installing
a central EACPT congress bureau.
Although the large biannual meetings allowed many clini-
cal pharmacologists to meet and discuss new developments in
their discipline, there was a growing feeling that there should
also bemeetings organized on a specific topic. Thesemeetings
with a smaller audience would facilitate interaction and ex-
change of knowledge and would reduce barriers for young
clinical pharmacologists and trainees to approach and directly
learn from the more experienced (older) colleagues.
Furthermore, these meetings would allow the organization of
specific Bhow-to^ sessions. In the beginning, these meetings
were organized as Bsummer schools^, and most of these sum-
mer schools were devoted to teaching aspiring clinical phar-
macologists in broad aspects of the specialty. For example, the
7th EACPT Summer School, organized in Alexandroupolis,
Greece, in September 2009 by Professors Ingolf Cascorbi and
Vangelis Manolopoulos introduced young (and not-so-young)
pharmacologists, other clinicians and researchers to the prin-
ciples and core subjects of clinical pharmacology covering
topics such as the general principles of clinical pharmacology,
r a t i o n a l d r u g u s e , p h a r m a c o e p i d em i o l o g y ,
pharmacogenomics/personalized medicine, clinical trials,
and emerging topics.
From 2014 onwards, these meetings were renamed to
BFocus meetings^. This renaming did not only allow the or-
ganization of meetings all year around (and not specifically in
summer), but also emphasized the opportunity to really focus
in depth on a certain topic, therefore not only attracting juniors
but also providing a program that is of interest to senior clin-
ical pharmacologists with a specific interest in that topic.
Together with the renaming of this kind of meeting, the way
they were managed also changed: a protocol was established
for submitting and reviewing a proposal for an EACPT focus
meeting and for proposing speakers from varied European
countries. The first EACPT focus meeting was organized in
2014 by Prof Gerard Rongen and internists at Radboudumc in
Nijmegen entitled Bdrugs to fight cardiovascular damage’.
The 3-day meeting was very well attended (85 participants),
not only by European clinical pharmacologists but also by
colleagues from Asia, USA, and Australia (a trend that also
Table 1 Aims of the European Association for Clinical Pharmacology
and Therapeutics
a) Promoting the use of clinical pharmacological services in healthcare
delivery
b) Improving and harmonizing the teaching of the rational use of drugs at
both undergraduate and postgraduate levels
c) Contributing with clinical pharmacological expertise to state policy
decisions regarding the regulation of drugs in Europe
d) Arranging scientific meetings, workshops, and courses in clinical
pharmacology and therapeutics in Europe
e) Utilizing the skills of clinical pharmacology and therapeutics in
counteracting misuse of prescriptions drugs and other chemical
substances
f) Promoting problem and patient-orientated drug information about
medicines for physicians and other health professionals
g) Increasing the input of clinical pharmacological skills in the evaluation
of drugs
h) Promoting high professional standards in the prescribing of drugs
i) Promoting high ethical standards in clinical drug research
j) Promoting the exchange of opinions in individual countries with regard
to existing differences in clinical pharmacology and therapeutics
k) Encouraging collaboration with other agencies interested in clinical
pharmacology and therapeutics e.g. WHO, European Regulatory
Network, IUPHAR
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occurs for the large EACPT congresses). Speakers included
clinical pharmacologists as well as cardiovascular experts
from other disciplines such as radiology, cardiology, endocri-
nology, and molecular biology and covered topics from mol-
ecule to man, including state of the art lectures on the patho-
genesis of atherosclerosis, hyperaldosteronism, functional
vascular imaging, ischemia-reperfusion injury and pathophys-
iological and pharmacological implications of the (gut)
microbioma. In addition to lectures and poster sessions, Bhow
to^ sessions were organized to learn specific ultrasound tech-
niques to image blood vessels and to measure vascular func-
tion. Based on this template, in 2016, a successful focus meet-
ing entitled BHow to Assess Medicines from Research to
Clinical Practice BEfficacy, Effectiveness, and Economic –
3E Assessment^ was organized in Opatia (Croatia) by
Professor Dinko Vitezic with a total of 138 attendees and
lecturers from 27 countries. This was followed by a smaller
focus meeting in 2018 organized by Professor Coleman and
his team in Birmingham (UK) on BInnovations in Clinical
Pharmacology and Therapeutics Education^ attended by 52
attendees from 14 countries.
EACPT started as an umbrella organization of European
societies for clinical pharmacology. Eachmember society puts
forward delegates to the EACPT council depending on the
size of their national society. The councilors have voting rights
and are responsible for electing the executive committee,
overseeing the finances, and procedural issues of the associa-
tion. To increase the involvement of individual clinical phar-
macologists in EACPT activities, from 2015 onwards,
EACPTmemberships were offered to individual clinical phar-
macologists, and managed by a professional societal manage-
ment office. Individual members can contribute to voting for
the various awards, and collaborate via the website in
online discussion forums.
Working groups
In order to ensure ongoing collaborations between formal
meetings, the association has a number of working groups.
Funding is available for each of the working groups in order
to help them deliver any planned activities.
Education
Soon after the foundation of the EACPT, a small group of
education-minded clinical pharmacologists was invited by
Prof. Michael Orme (UK) to form the EACPT Education
Subcommittee. They realized that the way that they were
taught the principles and practice of rational prescribing was
not the best for future prescribers. The pharmacology curric-
ulum in many institutions did not prepare future medical prac-
titioners well for the science and art of prescribing. The
learning goals were derived from pre-clinical lectures on basic
pharmacology encompassing detailed knowledge on the
working mechanisms of too many drug classes and based on
tedious reference texts. This was often followed in the
Bclinical phase^ by an experienced clinician teaching about
the disease and how to diagnose it whilst spending only a few
minutes on pharmacotherapy saying Byou can find that in the
guideline later on^. Traditionally every junior doctor would
start clinical practice with responsibility for a lot of prescrib-
ing but actually not really prepared for the job. This situation
was pictured strikingly in an editorial by Ramsey [7] (see
Fig. 1).
In 1995, the CPT education frontrunners showed a positive
effect of a problem-based learning course in pharmacotherapy
for undergraduate medical students in an international ran-
domized controlled trial [8]. The course was based on the
WHO Guide to good prescribing [9] later followed by the
teachers’ guide to good prescribing in 2003 [10]. It was key
leaders from EACPT such as Theo de Vries and Hans
Hogerzeil (WHO) who led these important collaborative ef-
forts to provide standardized resources available to all educa-
tors worldwide.
In 2007, in London, the EACPT and the British
Pharmacological Society (BPS) jointly organized a meeting
to discuss how to prepare junior doctors for safe prescribing
[11]. Led by David Webb and Simon Maxwell, the meeting
was attended by representatives from 12 European countries
and addressed the following topics: (i) the state of undergrad-
uate education in clinical pharmacology in Europe, (ii) the
knowledge and competencies in relation to medicines that
should be expected of a new graduate, (iii) assessments that
might demonstrate that this minimum standard had been
reached, (iv) a curriculum that might help medical students
to achieve this standard, and (v) how competence can be de-
veloped in the postgraduate phase. Although several ideas and
lines of action were decided during that meeting, almost all of
Fig. 1 An impression of the situation of teaching pharmacotherapy. On
the left the clinical pharmacology professor on his Clinical Pharmacology
Continent (CPC) is beavering away at his research, quite oblivious to
what is happening on the General Practice Island (GPI) where most of
the drugs are prescribed. Because of his research, the clinical pharmacol-
ogy professor is also not aware of the increasing number of students
trying in vain to get his attention in order to be taught therapeutics. The
students are seen struggling across the gap towards the real world of
medical practice, ill-prepared for the task facing them, and some do not
make it
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these challenges remain open today, including the introduc-
tion of a BEuropean Prescribing License^. Over the last
10 years, many further education initiatives have been under-
taken using different novel educational principles such as
learning by doing (in a student-led polypharmacy clinic), se-
rious gaming, peer teaching, and simulation training.
Objective Structured Clinical Examinations (OSCE) have
been developed to test prescribing skills and online assess-
ments (like the UK’s Prescribing Safety Assessment (PSA)),
and web-based e-learning platforms (like Pscribe) have been
developed often on a national scale [12] (https://www.pscribe.
nl/en-GB/Entrance/Home/Index). Plans are in place to spread
many of these innovations in similar or associated forms in
other European countries through the work of the education
group.
Now, in 2019, the EACPT Education Working Group is an
active group with 10 core members and many more associate
members (https://www.eacpt.eu/working-groups/education/
working-groups-and-projects/). The group has a role in
organizing EACPT symposia and focus meetings, expert
working parties, performing research in CPT education,
building a network for European CPT teachers and
developing new tools for CPT teaching. With the EACPT
ambition to improve the level of undergraduate and
postgraduate pharmacotherapy/prescribing training in
Europe, the Education Working Group has recently taken
the initiative to develop an international training and assess-
ment program that will be freely available online for all
European universities interested in a platform to increase the
quality of their CPT curriculum [13].
The education working group is a real strength of the asso-
ciation, and one of the founding aims to improve and harmo-
nize the teaching of the rational use of prescribing has come a
long way in 25 years. There are many other benefits that have
come from European Clinical Pharmacologists educating
young students and doctors in the art of prescribing, not least
that exposure to role model physicians during training serves
as a way to attract young people into the specialty. There are
however many challenges that CPT education will have to
face in the next 25 years such as the broadening of prescribing
activity to other professions, the impact that electronic pre-
scribing and other health technology will have on our learners
in practice, and the ever-increasing complexity of therapeutic
options. Nevertheless, not only is there a lasting legacy in this
area but also there is a thriving body of enthusiastic educators
within EACPT to face these challenges in the future.
Young clinical pharmacologist working group
The core competencies for education in clinical pharmacology
are well established throughout Europe but poorly harmo-
nized within the National training programs. Harmonized
training at undergraduate and postgraduate levels needs to be
addressed in a collaborative approach. Opportunities for ca-
reer development in clinical pharmacology also differ among
European countries. Moreover, networking for young clinical
pharmacologists is also a major goal in order to enhance col-
laborations and partnerships for education, research, and train-
ing through the European CP societies. To help in these mat-
ters, two successive EACPT chairs (Gonzalo Calvo (Spain)
and Tabassome Simon (France)) decided to help young clin-
ical pharmacologists to organize a pre-congress meeting be-
fore each EACPT biannual meeting. The goal was to stimulate
discussions, exchange experiences, and provide networking
opportunities between CP trainees and senior members of
EACPT. The first meeting was organized in June 2015 in
Madrid followed in June 2017 in Prague by Joaquin Saez
(Spain) andMatthieu Roustit (France). Clinical pharmacology
trainees were the main actors of these meetings which were
both lively and friendly thus furthering attendees’ professional
development and career aspirations. For the Prague Meeting
in 2017, the EACPT EC also decided for the first time to
further encourage and make more visible the engagement
and involvement of these younger pharmacologists, by asking
young CPs to co-chair four oral sessions with a senior
pharmacologist.
To facilitate the mobility and collaborations between young
and senior pharmacologists, the young clinical pharmacolo-
gists working group together with the research group also
organized a survey of research centers in clinical pharmacol-
ogy in order to list relevant contact, area of research interests
and availability for PhD and post-doc positions. The associa-
tion plans to build on the small scale initial response by build-
ing up a contemporary list of active research centers and op-
portunities across Europe.
The future EACPT meeting in Stockholm will also be a
great opportunity for young clinical pharmacologists to active-
ly participate in a third pre-congress meeting as well as to the
main congress meeting.
Regulatory affairs
The EACPT also advises health policy makers on criteria for
approving drugs and for regulating medicines after licensing
for clinical use. As one of the leading societies in the field of
translational and clinical drug development, EACPT is fre-
quently involved in the review of guidelines by regulators
such as the European Medicines Agency (EMA). This in-
volves interactions with EMA committees like CHMP
(Committee for Medicinal Products for Human Use) in par-
ticular in the field of efficacy and safety guidelines and other
multidisciplinary guidelines. For this task, during the 3–
6 month period of release for consultation, coordinators are
nominated by the society that collect input from experts in the
respective field of clinical pharmacology.
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In 2013, the European Medicines Agency launched work-
ing parties for leading European healthcare professional orga-
nizations to encourage interactions between European regula-
tors of medicines and experts in health-related disciplines with
regard to providing safe and effective medicines for EUmem-
ber countries and the wider world.
The EACPT was an inaugural member of the EMA’s
Healthcare Professionals’ Working Party (HCPWP), with
EACPT past-president Professor Gonzalo Calvo as its
founding and current co-chair. The EACPT through its dele-
gates has contributed to the activities of the HCPWP through
membership of and co-chairing of topic areas for social media,
digital media for health, supporting patient engagement in use
of medicines and minimizing medication errors. EACPT del-
egates have also since 2013 regularly organized sessions on
these and related topics within the twice-yearly conferences
for the over 60 EMA stakeholder health professional and pa-
tient organizations.
Research
For EACPT as a scientific society, promoting research is one
of the key tasks. The main platform for sharing the most ex-
citing research in clinical pharmacology is the biannual con-
gress organized by the association. The meeting hosts hun-
dreds of young and senior scientists for discussion of past
research activities and accelerates the building of novel col-
laborations and science networks. A separate research work-
ing group has been more recently set up to promote collabo-
rative work in the discipline. Plans for the working group
going forward involve the selection of monthly publication
highlights in the field of clinical pharmacology and discussion
of these manuscripts at our webpage.
Lifetime achievement awards in clinical
pharmacology
Since 2009, EACPT lifetime achievement awards in clinical
pharmacology have been recognizing significant achieve-
ment, both for the benefit of science and also for the benefit
and health of the specialty, over a whole working lifetime. The
award recipients all went through remarkable careers whose
discoveries and scientific results have fundamentally contrib-
uted to clinical pharmacology. Being some of the most cited
pharmacologists in the world, many are listed by Thomson
Reuters for years as ISI highly cited researchers in pharmacol-
ogy. They also demonstrated a long-standing personal contri-
bution in the clinical or educational field of clinical pharma-
cology that contributed towards the significant development
of the discipline. They were chosen by the EACPT council
following nominations from members of EACPT council and
national member societies. Since 2015, the award winners are
asked to give an award lecture to the congress and provide a
paper for publication in the official EACPT journal.
The first award was presented by EACPT to Professor
Folke Sjöqvist from Sweden in 2009 in Edinburgh. Professor
Sjöqvist has been a leading clinical pharmacologist throughout
Europe for decades in terms of research in the whole field of
clinical pharmacology (TDM, pharmacogenetics, rational drug
information, pharmacovigilance), education (112 fellows from
37 countries), and the development of the discipline with the
publication of the manifesto in collaboration with WHO [14].
In 2011, Professor Sir Colin Dollery from the UK received
the award in Budapest. His research focused on hypertension
and drug safety. Appointed as professor of clinical pharmacol-
ogy in 1968, Sir Colin had a wide and distinguished career. He
was the founding chairman of the clinical pharmacology sec-
tion of the British Pharmacological Society and trained nu-
merous clinical pharmacologists in the UK. He chaired the
organizing committee of the First World Conference on
Clinical Pharmacology (held in London in 1980) and was
the president of IUPHAR from 1987 to 1990.
During the Geneva Congress in 2013, Professor Sir
Michael Rawlins, UK, and Professor Carlo Patrono, Italy,
were jointly awarded. Besides his outstanding scientific con-
tributions, Professor Sir Michael was the first chairman of the
National Institute for Health and Clinical Excellence (NICE),
one of the world’s most important healthcare organizations,
which published guidelines on the use of medicines and health
technologies within the National Health Service based on clin-
ical and cost-effectiveness. Professor Carlo Patrono’s research
has characterized the human pharmacology of aspirin as an
inhibitor of platelet COX-1 and provided the basis for the
development of low-dose aspirin as an antithrombotic agent.
He also contributed to characterizing the human pharmacolo-
gy of COX-2 inhibitors and evaluating their cardiovascular
effects in different clinical settings.
In 2015, Prof Michel Eichelbaum, Germany, was awarded
in Madrid. His primary research interest has been the pharma-
cogenetics of drug metabolizing enzymes and transporter pro-
teins. In 1975, he discovered a genetic polymorphism in the
oxidation of the antiarrhythmic sparteine, which later became
known as CYP2D6 polymorphism. Later, he became involved
in research on factors involved in the regulation of drug-
metabolizing enzymes and transporters with special emphasis
on nuclear receptors.
Professor Pertti J. Neuvonen, Finland, was awarded in
Prague in 2017. His research focused on drug safety and indi-
vidual variability in drug response, particularly on drug inter-
actions and their mechanisms. Since 1970, his research group
has found more than 200 previously unrecognized, clinically
important drug-drug interactions and several significant food-
drug interactions.
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Professor Urs Albert Meyer will receive the 2019 lifetime
achievement award in Stockholm. His research has focused on
interindividual variations in drug response, from studying the
drug sensitivity of the pharmacogenetic disease porphyria to
the pharmacogenomics of drug disposition and its
coregulation by drug interactions and environmental factors.
He identified the genes and mutations in these genes causing
variation in drug response and developed the first pharmaco-
genetic DNA tests, initially for the CYP2D6 and NAT2 genes.
Urs Meyer has been highly committed to the teaching of clin-
ical pharmacology to medical students and to training pro-
grams in drug development sciences (71 graduate students,
62 postdoctoral fellows and > 35 of his previous collaborators
now in academic positions worldwide).
Best scientific papers
Since 2009, the EACPT best scientific paper prize is awarding
the best scientific paper on a topic relevant to clinical pharma-
cology published by a European clinical pharmacologist in the
2 years before each EACPTcongress based on criteria relating
to the scientific quality of the work, broader impact on sci-
ence, and importance of the work in the context of healthcare
delivery). The previous award recipients are shown in Table 2.
.
EACPT in 2019
EACPT is the leading society in Europe serving the European
clinical pharmacology and therapeutic community. As a soci-
ety of societies, we have 35 national societies affiliated to
EACPT encompassing over 4000 members across the conti-
nent. However, EACPT also has global reach with many
members of the global clinical pharmacology community at-
tending our biennial congresses, focus meetings, and
contributing to the wider work of the association. For exam-
ple, our last congress attracted nearly 600 delegated from 55
countries around the world. We actively collaborate with a
wide range of other European organizations and societies in-
cluding the European Medicines Agency (EMA), the
European Union of Medical Specialists (UEMS), The
Federation of European Pharmacological Societies
(EPHAR), European Drug Utilisation Research Group
(EuroDURG); as well as International Societies, in particular
the International Union of Basic and Clinical Pharmacology
(IUPHAR). The association has always aimed to be inclusive
from its genesis onwards and we are proud to serve a global
community of clinical pharmacologists.
Challenges and opportunities for clinical
pharmacology in the next 25 years
Clinical pharmacology is not without challenges, as readers of
this journal will be aware, not least the visibility of the disci-
pline amongst our scientific, physician and other healthcare
colleagues. The challenges to the discipline of clinical phar-
macology have been well represented in the literature over
almost as many years as the specialty has existed [15].
Recent considerations suggest that the specialty is challenged
in carving out its unique identity amongst a widening breadth
of prescribers in healthcare and translational scientists in aca-
demia that threatens the future of the specialty [16]. It is the
very breadth of therapeutics that is both a strength and weak-
ness of the specialty of clinical pharmacology, as the broad
scope of practice can be difficult to place in the modern med-
ical specialist model, and yet the specialty offers almost lim-
itless opportunities to young practitioners.
Another challenge, which might either be a threat or an
opportunity, is the increasing use of omics techniques and
biomarkers to evaluate drug effects, whether therapeutic or
adverse. Clinical pharmacology must be to the forefront of
these innovations that may well transform the way that clinical
Table 2 EACPT best scientific paper prize award winners
Best scientific
paper author
Year
received
City, Country Title Journal reference
Ian Wilkinson 2009 Cambridge, UK Central pressure: variability and impact of cardiovascular
risk factors: the Anglo-Cardiff Collaborative Trial II
Hypertension 2008; 51: 1476-82
Tabassome Simon 2011 Paris, France Genetic determinants of response to clopidogrel and
cardiovascular events
New England Journal of Medicine
2009; 360(4): 363–75.
David Devos 2013 Lille, France Methylphenidate for gait hypokinesia and freezing
in patients with Parkinson’s disease undergoing
subthalamic stimulation
Lancet Neurology 2012; 11(7): 589–596
Nicholas Bateman 2015 Edinburgh, UK Reduction of adverse effects from intravenous
acetylcysteine treatment for paracetamol poisoning
Lancet 2014; 383(9918): 697–704.
David Webb 2017 Edinburgh, UK Spironolactone versus placebo, bisoprolol, and doxazosin
to determine the optimal treatment for drug-resistant
hypertension (PATHWAY-2)
Lancet 105; 386(10008): 2059–68.
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trials are designed and that patients are diagnosed, dosed and/
or monitored.
More generally, academic pharmacology is and should in-
creasingly be translational so as: [1] to decipher drug effects
(in particular adverse effects that often poorly understood), the
main sources of drug response variability and the determinants
of drug benefit-risk balance; [2] to design and conduct smarter
clinical trials; [3] to detect low signals of serious adverse ef-
fects; and most importantly, [4] to orchestrate precision
medicine.
Within healthcare and wider society, there is a push to-
wards more cost-efficient healthcare which requires better for-
mularies, guidelines for medication use, and ways to monitor
safe and effective medication use; all activities which are well
served by clinical pharmacologists working across health sec-
tors [17]. A recent impact assessment in the UK has estimated
that each £1 spent on hiring additional clinical pharmacolo-
gists has the potential to reduce health service costs by almost
£6 [18].
It is for all of these reasons that EACPT remains a vibrant
community of scientists and multidisciplinary practitioners
that are well placed to serve healthcare, regulation, industry,
and many other sectors well for the next 25 years and to
promote innovations in the discovery, assessment and best
use of drugs in the European population.
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